Primary Sclerosing Cholangitis (PSC) is a rare, progressive liver disease characterized by inflammation and scarring of the bile ducts that causes them to narrow. Over time, the bile duct damage caused by PSC prevents the liver from functioning properly. The current treatment landscape focuses on reducing symptoms and managing them effectively. However, there is a pressing need for developing curative treatment options to address its rising prevalence.

The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity
Increasing prevalence of inflammatory bowel disease (IBD) poses a significant market opportunity for PSC treatment developers. Studies suggest that PSC occurs in 7-10% of people with ulcerative colitis, the most commonly diagnosed form of IBD. Rising IBD burden worldwide is reflecting onto a surge in PSC cases as well. Development of novel, effective treatment strategies specifically targeting the immune-mediated pathogenesis of IBD-related PSC can address a large unmet need. This presents lucrative prospects for biopharmaceutical companies in the coming years.

Porter’s Analysis
Threat of new entrants: The Primary Sclerosing Cholangitis market has moderate threat of new entrants due to the high R&D costs associated with drug development and clinical trials required to enter this market.
Bargaining power of buyers: The bargaining power of buyers is moderate since there are limited treatment options available for Primary Sclerosing Cholangitis.
Bargaining power of suppliers: The bargaining power of suppliers is high due to the specialized intellectual property required for drug development in this market.
Threat of new substitutes: The threat of new substitutes is low since there are limited treatment alternatives currently available for Primary Sclerosing Cholangitis.
Competitive rivalry: The competitive rivalry is high due to the presence of key players focusing on developing novel drugs and treatment options.

SWOT Analysis
Strengths: Growing research funding and support groups, unmet medical needs.
Weaknesses: Limited treatment options, complexity of disease diagnosis and management.
Opportunities: Developing personalized medicines, emerging economies.
Threats: High R&D costs, regulatory challenges.

Key Takeaways
The global Primary Sclerosing Cholangitis Market Growth is expected to witness high growth over the forecast period of 2023 to 2030 supported by increasing research funding and emerging treatment options. The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030.

Regional analysis shows that North America currently dominates the global market due to presence of key market players and growing research initiatives in the region. Europe is also a major market for Primary Sclerosing Cholangitis supported by increasing awareness. The Asia Pacific region is expected to be fastest growing market during the forecast period owing to rising healthcare expenditure and improving access to diagnosis and treatment in countries such as China and India.

Key players operating in the Primary Sclerosing Cholangitis market are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.

For more insights, read- https://www.pressreleasebulletin.com/primary-sclerosing-cholangitis-market-trends-size-and-share-analysis/